Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

被引：32

作者：

Eisen, T. ^{[1
]}

Marais, R. ^{[2
]}

Affolter, A. ^{[2
]}

Lorigan, P. ^{[3
]}

Robert, C. ^{[4
]}

Corrie, P. ^{[1
]}

Ottensmeier, C. ^{[5
]}

Chevreau, C. ^{[6
]}

Chao, D. ^{[7
]}

Nathan, P. D. ^{[8
]}

Jouary, T. ^{[9
]}

Harries, M. ^{[10
]}

Negrier, S. ^{[11
]}

Montegriffo, E. ^{[12
]}

Ahmad, T. ^{[13
]}

Gibbens, I. ^{[13
]}

James, M. G. ^{[13
]}

Strauss, U. P. ^{[14
]}

Prendergast, S. ^{[12
]}

Gore, M. E. ^{[13
]}

机构：

[1] Addenbrookes Hosp, Dept Oncol R4, Cambridge Biomed Res Ctr, Cambridge CB2 0QQ, England

[2] Inst Canc Res, Div Canc Biol, London SW3 6JB, England

[3] Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[4] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[5] Southampton Univ Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England

[6] Inst Claudius Regaud, Dept Med Oncol, F-31052 Toulouse, France

[7] Royal Free Hosp, Canc Serv Div, London NW3 2QG, England

[8] Mt Vernon Canc Ctr, Canc Serv Div, Northwood HA6 2RN, Middx, England

[9] Hop St Andre, Dept Dermatol, F-33075 Bordeaux, France

[10] Guys & St Thomas Hosp, Canc Serv Div, London SE1 7EH, England

[11] Ctr Leon Berard, F-39373 Lyon, France

[12] Bayer PLC, Newbury RG14 1JA, Berks, England

[13] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England

[14] Bayer Schering Pharma, D-51368 Leverkusen, Germany

来源：

BRITISH JOURNAL OF CANCER | 2011年 / 105卷 / 03期

关键词：

melanoma; sorafenib; dacarbazine; combination therapy; biomarker; RANDOMIZED DISCONTINUATION TRIAL; AMERICAN-JOINT-COMMITTEE; MULTIKINASE INHIBITOR; MALIGNANT-MELANOMA; COMBINATION; RAF; BRAF; TEMOZOLOMIDE; CARBOPLATIN; MUTATIONS;

D O I：

10.1038/bjc.2011.257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

METHOD: The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study. RESULTS: In the phase I study, three patients were treated with sorafenib 200 mg twice daily (b.i.d.) plus 1000 mg m(-2) dacarbazine on day 1 of a 21-day cycle and 15 patients had the sorafenib dose escalated to 400 mg b.i.d. without reaching the maximum tolerated dose of the combination. In the phase II study (n = 83), the overall response rate was 12% (95% CI: 6, 21): one complete and nine partial, with median response duration of 46.7 weeks. Stable disease was the best response in 37%; median duration was 13.3 weeks. Median overall survival (OS) was 37.0 weeks (95% CI: 33.9, 46.0). CONCLUSION: Oral sorafenib combined with dacarbazine had acceptable toxicity and some antineoplastic activity against metastatic melanoma. British Journal of Cancer (2011) 105, 353-359. doi:10.1038/bjc.2011.257 www.bjcancer.com Published online 12 July 2011 (C) 2011 Cancer Research UK

引用

页码：353 / 359

页数：7

共 50 条

[1] Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
T Eisen
R Marais
A Affolter
P Lorigan
C Robert
P Corrie
C Ottensmeier
C Chevreau
D Chao
P D Nathan
T Jouary
M Harries
S Negrier
E Montegriffo
T Ahmad
I Gibbens
M G James
U P Strauss
S Prendergast
M E Gore
British Journal of Cancer, 2011, 105 : 353 - 359
[2] An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma
Eisen, T.
Marais, R.
Affolter, A.
Lorigan, P.
Ottensmeier, C.
Robert, C.
Corrie, P.
Chevreau, C.
Erlandsson, F.
Gore, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
R Plummer
P Lorigan
E Brown
R Zaucha
V Moiseyenko
L Demidov
V Soriano
E Chmielowska
R Andrés
G Kudryavtseva
C Kahatt
S Szyldergemajn
S Extremera
B de Miguel
M Cullell-Young
H Calvert
British Journal of Cancer, 2013, 109 : 1451 - 1459
[4] OPEN-LABEL PHASE II STUDY OF SORAFENIB plus DACARBAZINE IN PATIENTS WITH ADVANCED METASTATIC MELANOMA
Gonzalez-Larriba, J. L.
Guillem, V.
Marmol, M.
Valladares, M.
Arrivi, A.
Pastor, P.
Garcia-Garcia, M.
ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
[5] Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
Plummer, R.
Lorigan, P.
Brown, E.
Zaucha, R.
Moiseyenko, V.
Demidov, L.
Soriano, V.
Chmielowska, E.
Andres, R.
Kudryavtseva, G.
Kahatt, C.
Szyldergemajn, S.
Extremera, S.
de Miguel, B.
Cullell-Young, M.
Calvert, H.
BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1451 - 1459
[6] Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Garcia, Jairo A.
Roberts, Lewis R.
JOURNAL OF HEPATOLOGY, 2012, 56 (02) : 486 - 487
[7] Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Park, Joong-Won
Finn, Richard S.
Kim, Jun Suk
Karwal, Mark
Li, Ruby K.
Ismail, Fuad
Thomas, Melanie
Harris, Rosemarie
Baudelet, Christine
Walters, Ian
Raoul, Jean-Luc
CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1973 - 1983
[8] Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Bi, Feng
Qin, Shukui
Gu, Shanzhi
Bai, Yuxian
Chen, Zhendong
Wang, Zishu
Ying, Jieer
Lu, Yinying
Meng, Zhiqiang
Pan, Hongming
Yang, Ping
Zhang, Helong
Chen, Xi
Xu, Aibing
Liu, Xiufeng
Meng, Qiu
Wu, Liqing
Chen, Feng
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Sintilimab combined sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase II study.
Wang, Jiabei
Liu, Lianxin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16182 - E16182
[10] A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma
O'Neill, Penny A.
Butt, Mohammad
Eswar, Chinnamani V.
Gillis, Pat
Marshall, Ernest
MELANOMA RESEARCH, 2006, 16 (03) : 245 - 248

← 1 2 3 4 5 →